Navigation Links
Novasys Medical's Debra Reisenthel Named ABL's 2010 “Leadership in Innovation” Awardee
Date:3/2/2010

Debra Reisenthel, President and CEO of Novasys Medical Inc., will receive the Adaptive Business Leaders Organization (ABL)’s 2010 “Leadership in Innovation” Award and make the Keynote presentation at ABL's 12th Annual Innovations in HealthcareSM Awards Event, on April 28, in Newport Beach, California.

Santa Ana, CA (PRWEB) March 2, 2010 -- Debra Reisenthel, President and CEO of Novasys Medical Inc., will receive the Adaptive Business Leaders Organization (ABL)’s 2010 “Leadership in Innovation” Award and make the Keynote presentation at ABL's 12th Annual Innovations in HealthcareSM Awards Event, on April 28, in Newport Beach, California.

Debra Reisenthel has led Novasys Medical, a women’s health company, since its inception, in 2001. Along the way, she has raised $90 million in venture capital to see the company’s flagship product, the Renessa® System, through product development, animal studies, human clinical trials, FDA approval, market acceptance, and widespread reimbursement. In a market with huge challenges, few visionaries remain a company’s chief executive throughout the entire progression, from idea to commercialization.

Renessa was named the 2009 Most Promising New Product, selected by industry CEOs, at the Phoenix Medical Device and Diagnostic Conference. Also since 2009, Renessa has received several positive insurance coverage decisions, including approvals for nationwide coverage from Aetna, a positive Blue Shield of California Technology Assessment (CTAF), and coverage approvals from seven of the ten Medicare regions - enabling Medicare to cover Renessa for over 75% of insured women nationwide.

In accepting ABL’s “Leadership” Award, Reisenthel joins the impressive circle of ABL’s previous “Leadership in Innovation” Awardees. In 2008, the Award went to Patrick Soon-Shiong, visionary philanthropist and founder of Abraxis Bioscience and Health; in 2007, to Steve Case, founder of Revolution Health and AOL; in 2007, to Steve Burd, CEO and chief wellness advocate of Safeway Inc.; in 2006, to Ken Kizer, MD, visionary behind the VA’s VistA Electronic Medical Record System, as the US Dept of Veterans Affairs’ Under Secretary for Health; in 2005, to Kent Thiry, CEO of DaVita, an innovative provider of health education and dialysis services; and in 2004, to Leonard Schaeffer, CEO of WellPoint Health Networks, one of the nation’s largest health plans.

Also at the April 28th Innovations in HealthcareSM Event, ABL ABBY Awards will be presented to three of the nine companies presenting their innovative approaches to the delivery of healthcare, health information and telecommunications technologies, and innovative medical devices. The Award winners will be chosen from Finalists selected for best meeting ABL’s criteria of having an innovative product/service that is approved for use in the U.S. marketplace, with clinical and financial metrics that prove their technology or approach reduces the cost of providing quality healthcare. ABBY Award winners will be selected via secret ballot by ABL Members, after viewing presentations at the Event made by the CEO or senior division executive representing each Finalist company.

Now in its 12th year, ABL’s Innovations in HealthcareSM Awards Event recognizes organizations that have demonstrated transformative advances in medical devices, diagnostics, therapeutics, information technology and approaches to providing care and coverage, decreasing the numbers of uninsured, and engaging healthcare consumers more actively in their care and health status, all of which reduces the cost of providing quality healthcare. Details about the Innovations in HealthcareSM Awards Event can be found at www.abl.org/IIH2010.htm.

About the Adaptive Business Leaders Organization
ABL supports the needs of its Member CEOs by providing a place for top-level executives to draw on the experience, knowledge and skill sets of their peers in a vertical industry, personal advisory board setting. Members meet once a month for a half-day Round Table session with a group of peer senior executives from non-competing companies. Members also gather several times a year at workshops and conferences to exchange ideas and connect with other chief executives. ABL's Chief Executive Leadership Development Round Table program is offered in California's Greater Los Angeles, Orange, San Francisco and Santa Clara Counties. More information can be found at http://www.abl.org.

###

Read the full story at http://www.prweb.com/releases/Innovationsin/Healthcare/prweb3672054.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Novasys Medical Receives $18.95 Million in Second Tranche of Series D Financing
2. Aetna Now Covers Novasys Medicals Renessa(R) Treatment for Incontinence in Women
3. Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board
4. Renowned Medical Tourism Industry Expert and Author Josef D. Woodman Joins Satori World Medical's Strategic Advisory Board
5. Hepatitis C Therapeutic DNA Vaccine Delivered by Inovio Biomedical's Electroporation Technology Reduces Viral Load by Up to 99.7% : Clinical Data Presented at Annual Scientific Meeting of the American Association for the Study of Liver Diseases
6. Emmy Award Winning Actress Debra Messing Visits Zimbabwe
7. Council for American Medical Innovation Names Debra R. Lappin President
8. NaturalNews Posts Audio Interview with Consumer Chemical Expert Debra Lynn Dadd on Bisphenol-A
9. Debra Strickland joins Foresight Corporation in time for HIPAA 5010 Mandate
10. Lauren Debrauwere Released from Northwestern Memorial Hospital
11. The G&P Foundation Celebrates 10 Years of Funding Life Saving Research at The 2007 Angel Ball Honoring Glenda Bailey, Debra L. Lee, Dr. Stephen D. Nimer and the Late H.H. Sheik Zayed Bin Sultan Al Nahyan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology: